GlassScriptPhysician profile
Guldeniz Doganay
NPI 1114023918
$1,256.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $298 · 2021: $517 · 2022: $284.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $204.25 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $103.25 | 2019-2022 | |
| Pfizer INC. | $100.39 | 2019-2022 | |
| Esperion Therapeutics, INC. | $65.80 | 2020-2021 | |
| Novo Nordisk INC | $64.81 | 2021 | |
| Abbott Laboratories | $63.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $54.94 | 2020-2021 | |
| Bardy Diagnostics, INC. | $52.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $48.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $33.89 | 2020-2021 | |
| Genentech USA, INC. | $32.34 | 2020 | |
| Lilly USA, LLC | $29.48 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.01 | 2020-2021 | |
| Amgen INC. | $23.01 | 2019 | |
| Sanofi Pasteur INC. | $18.42 | 2020 | |
| Edwards Lifesciences Corporation | $17.09 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guldeniz Doganay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.